Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway

被引:10
|
作者
Zhou, Haibin [1 ]
Lu, Jianfeng [1 ]
Yang, Chao-Yie [2 ]
Sun, Yi [3 ]
Wang, Shaomeng [1 ,4 ,5 ]
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN USA
[3] Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA
关键词
CRL3; UBC12/UBE2M; DCN1; Small-molecule inhibitor; Protein-protein interaction; CULLIN-RING LIGASES; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS; DRUG DISCOVERY; NEDD8; CONJUGATION; DEGRADATION; INHIBITORS; MECHANISM; LIGATION;
D O I
10.1007/978-981-15-1025-0_20
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein neddylation is one type of posttranslational modifications that regulates the activity of the substrate proteins. Neddylation modification is catalyzed by NEDD8-activating enzyme (NAE, E1), NEDD8-conjugating enzyme (E2), and NEDD8 ligase (E3) to attach NEDD8, an ubiquitin-like molecule, to a lysine residue of a substrate protein. The best known neddylation substrates are cullin family members, which are scaffold components of cullin-RING ligases (CRLs), and cullin neddylation is required for activation of CRLs. In mammalian cells, there are one E1, two E2s (UBC12/UBE2M and UBE2F), and over a dozen E3s. MLN4924, the first-in-class small-molecule inhibitor of NAE, blocks the entire neddylation modification to inactivate activity of all CRLs. MLN4924 is currently in the Phase I/II clinical trials for anticancer application. In the last few years, targeting protein-protein interactions of the neddylation complexes has been pursued as a potential strategy to selectively inhibit the activity of individual CRL. Analysis of the co-crystal structures of DCN1, a co-E3 for neddylation, and its binding partners UBC12 (a neddylation E2) suggested that it may be amenable for the design of potent, small-molecule inhibitors. In this chapter, we will review the discovery of small-molecule inhibitors that block the interactions of DCN1 with UBC12 (hereafter called DCN1 inhibitors) from a number of laboratories, including ours, leading to selective inactivation of CRL-1 and/or CRL-3. We will also discuss potential therapeutic applications of these small-molecule inhibitors.
引用
收藏
页码:349 / 362
页数:14
相关论文
共 50 条
  • [1] Targeting the DCN1-UBC12 protein-protein interaction: novel approaches and future directions
    Fang, Yuan
    Yu, Bin
    Liao, Guochao
    Liu, Hong-Min
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (22) : 2869 - 2871
  • [2] Targeting the DCN1-UBC12 Protein-protein Interaction for Selective Modulation of Cullin Substrates
    Fang, Yuan
    Yu, Lei
    Liao, Guochao
    Yu, Bin
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (17) : 1423 - 1425
  • [3] High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein Protein Interaction
    Zhou, Haibin
    Zhou, Weihua
    Zhou, Bing
    Liu, Liu
    Chern, Ting-Rong
    Chinnaswamy, Krishnapriya
    Lu, Jianfeng
    Bernard, Denzil
    Yang, Chao-Yie
    Li, Shasha
    Wang, Mi
    Stuckey, Jeanne
    Sun, Yi
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (05) : 1934 - 1950
  • [4] Structure-based design of highly potent small-molecule inhibitors of DCN1-UBC12 protein-protein interaction
    Zhou, Haibin
    Lu, Jianfeng
    Liu, Liu
    Bernard, Denzil
    Stuckey, Jeanne
    Sun, Yi
    Wang, Shaomeng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [5] Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction
    Wang, Shuai
    Zhao, Lijie
    Shi, Xiao-Jing
    Ding, Lina
    Yang, Linlin
    Wang, Zhi-Zheng
    Shen, Dandan
    Tang, Kai
    Li, Xiao-Jing
    Mamun, M. A. A.
    Li, Huiju
    Yu, Bin
    Zheng, Yi-Chao
    Wang, Shaomeng
    Liu, Hong-Min
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (05) : 2772 - 2797
  • [6] A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation
    Haibin Zhou
    Jianfeng Lu
    Liu Liu
    Denzil Bernard
    Chao-Yie Yang
    Ester Fernandez-Salas
    Krishnapriya Chinnaswamy
    Stephanie Layton
    Jeanne Stuckey
    Qing Yu
    Weihua Zhou
    Zhenqiang Pan
    Yi Sun
    Shaomeng Wang
    Nature Communications, 8
  • [7] A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation
    Zhou, Haibin
    Lu, Jianfeng
    Liu, Liu
    Bernard, Denzil
    Yang, Chao-Yie
    Fernandez-Salas, Ester
    Chinnaswamy, Krishnapriya
    Layton, Stephanie
    Stuckey, Jeanne
    Yu, Qing
    Zhou, Weihua
    Pan, Zhenqiang
    Sun, Yi
    Wang, Shaomeng
    NATURE COMMUNICATIONS, 2017, 8
  • [8] Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer
    Li, Anqi
    Ma, Ting
    Wang, Shuai
    Guo, Yueyang
    Song, Qianqian
    Liu, Hongmin
    Yu, Bin
    Feng, Siqi
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 173
  • [9] Discovery of novel small molecule inhibitors of the DCN1-Ubc12 interaction by high throughput screening technology
    Min, Jaeki
    Scott, Daniel C.
    Chai, Sergio C.
    Goktug, Asli N.
    Hammill, Jared T.
    Huang, Guochang
    Connelly, Michele C.
    Matheny, Amy
    Shelat, Anang
    Singh, Bhuvanesh
    Chen, Taosheng
    Schulman, Brenda A.
    Guy, R. Kiplin
    CANCER RESEARCH, 2016, 76
  • [10] Development of phenyltriazole thiol-based derivatives as highly potent inhibitors of DCN1-UBC12 interaction
    Zhou, Wenjuan
    Xu, Chenhao
    Dong, Guanjun
    Qiao, Hui
    Yang, Jing
    Liu, Hongmin
    Ding, Lina
    Sun, Kai
    Zhao, Wen
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 217